Page 2,293«..1020..2,2922,2932,2942,295..2,3002,310..»

Test Tube Burger Taste Test – Beef Made From Stem Cells Of Cows – Shmeat – Video

Posted: August 9, 2013 at 12:44 am


Test Tube Burger Taste Test - Beef Made From Stem Cells Of Cows - Shmeat
Test Tube Burger Taste Test - Beef Made From Stem Cells Of Cows.

By: Mass Tea Party

View post:
Test Tube Burger Taste Test - Beef Made From Stem Cells Of Cows - Shmeat - Video

Posted in Stem Cell Videos | Comments Off on Test Tube Burger Taste Test – Beef Made From Stem Cells Of Cows – Shmeat – Video

Today’s Dental News: Stem Cell Research Turns to Gingivae – Video

Posted: August 9, 2013 at 12:43 am


Today #39;s Dental News: Stem Cell Research Turns to Gingivae
On this week #39;s Wednesday Watch, learn about a new study about tissue regeneration that will be of interest to dentists, and hear about a chocolate study that...

By: TheWednesdayWatch

Originally posted here:
Today's Dental News: Stem Cell Research Turns to Gingivae - Video

Posted in Stem Cell Research | Comments Off on Today’s Dental News: Stem Cell Research Turns to Gingivae – Video

World's most expensive burger made from stem cells – Video

Posted: August 8, 2013 at 5:48 pm


World #39;s most expensive burger made from stem cells
Sa mga mahihilig sa burger, mag-ipon-ipon na kung gusto niyong matikman ang pinakamahal na burger sa buong mundo. Gawa sa stem cells ang tinaguriang "test tube burger" na nasa London.

By: TheABSCBNNews

Continue reading here:
World's most expensive burger made from stem cells - Video

Posted in Stem Cells | Comments Off on World's most expensive burger made from stem cells – Video

Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology

Posted: August 8, 2013 at 5:46 pm

VALENCIA, Calif., Aug. 8, 2013 /PRNewswire/ --Sanguine BioSciences, a biotechnology company enabling personalized medicine research, today announced a distribution partnership with AMS Biotechnology (AMSBIO) to make its products and services available to researchers in Europe.

Sanguine collects and de-identifies biospecimen, medical history and other data from patients diagnosed with severe and chronic diseases for use in biomarker research. Researchers traditionally obtain biospecimen through hospitals, but this process often proves inefficient as the focus for physicians and staff is on diagnosis and treatment, not facilitating research efforts. By connecting directly with patients, Sanguine can meet the needs of researchers and offer timely turnaround of biospecimen and medical data with diverse ranges for age, race, disease state, gender and treatments underway. The patient engagement tactics used by the company have led to a 95 percent retention rate, which also allow for follow-up draws for longitudinal studies.

"There is no denying that personalized medicine has become a significant area of interest for drug discovery, but there exists a gap between researchers who require biospecimen respective medical data, and patients who want to be a part of research efforts," said Brian Neman, founder and chief executive officer of Sanguine. "We have engaged hundreds of patient subjects, and built a library of specimen and data that can effectively bridge this gap. We look forward to partnering with AMSBIO to make this service accessible to researchers around the world working in different therapeutic areas."

Added Phillip Pridham-Field of AMSBIO, "Sanguine's patient retention efforts allow researchers to collect the data they need with better turnaround time and with the potential for longitudinal studies. We believe they will be an excellent addition to our current product offerings for researchers in life sciences."

Sanguine is able to meet, review disclosures and collect blood samples in a patient's home with its own phlebotomists in multiple major U.S. cities. Patients are also able to track how their de-identified biospecimen and data are used through the donor web-portal. The company is able to collect and process blood from patients with any disease and has already built large libraries in multiple chronic and severe conditions, including Huntington's disease, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis and others.

In order to maintain appropriate confidentiality, all samples are de-identified immediately upon collection. Sanguine maintains and reviews internal ethical guidelines for the procedures under high scrutiny from an independent review board.

About Sanguine

Sanguine BioSciences is a biotechnology company bridging the gap between patients and researchers developing personalized medicine. The company engages patients in biomedical research by delivering transparency throughout the research process. Sanguine collects and de-identifies patient-derived data in the form of biospecimen, and physician and self-reported information. These data are generated and then made available to researchers involved in drug and biomarker research and discovery with leading academic laboratories and companies, such as Vertex. (http://sanguinebio.com)

About AMS Biotechnology

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. With a range of molecular detection reagents and a significant Biorepository AMSBIO offers tissues, DNA, RNA, protein and tissue microarray products. Key research areas for AMSBIO include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.

Read more:
Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology

Posted in Biotechnology | Comments Off on Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology

Stem Cell Therapy Treatment for Transverse Myelitis by Dr Alok Sharma, Mumbai, India. – Video

Posted: August 8, 2013 at 5:45 pm


Stem Cell Therapy Treatment for Transverse Myelitis by Dr Alok Sharma, Mumbai, India.
Improvement seen after Stem Cell Therapy Treatment for Transverse Myelitis by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy PT assessment: Objectively : 1) Grade 3-4 spasticity in...

By: Neurogen Brain and Spine Institute

Read this article:
Stem Cell Therapy Treatment for Transverse Myelitis by Dr Alok Sharma, Mumbai, India. - Video

Posted in Stem Cell Therapy | Comments Off on Stem Cell Therapy Treatment for Transverse Myelitis by Dr Alok Sharma, Mumbai, India. – Video

California Stem Cell Agency on Lacks: Informed Consent Cannot Remove All Questions

Posted: August 8, 2013 at 1:59 pm

(Photo and caption from the stem cell agency blog item this morning.)
The $3 billion California stem cell
agency today weighed in on the Henrietta Lacks-NIH arrangement
restricting the use of her cell lines in research.
Writing on the agency's blog, Geoff
Lomax
, the agency's senior officer for its standards group, noted
that the DNA sequence of her cell line was published without the
knowledge of her descendants. Lomax said,

“The family was understandably upset
by the lack of consultation and in response the research team removed
the genome data from public access.”

Lomax continued,

“CIRM has benefited from these
efforts. We are currently supporting an initiative to collect tissue
samples from thousands of people with a range of incurable diseases
and create reprogrammed iPS cells from those tissues (here's
more about that initiative
). These cells will be a resource for
scientists worldwide working to understand and treat diseases. Part
of this initiative includes a consent process to make sure people who
donate fully understand how their cells will be used. (This process
is formally called informed consent.) 

“The informed
consent process includes a form that identifies the purposes of the
research and describes the way cells will be used. We are also
developing education materials that will help potential donors
quickly and easily understand the basic aspects of research that will
be conducted with those cells. The end result of this collaboration
with our grantees will be a process that is truly informative to
donors.

“The informed consent process can’t entirely
eliminate all future questions on the part of the donor, but it does
ensure that donors have a chance to understand how their cells will
be used and what information will be made public—something
Henrietta Lacks and her family never had.”  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/8PQGYcYpszg/california-stem-cell-agency-on-lacks.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on California Stem Cell Agency on Lacks: Informed Consent Cannot Remove All Questions

Skloots, Collins and More on Henrietta Lacks' Cell Line Deal

Posted: August 8, 2013 at 12:54 pm

More details about the unprecedented
arrangement involving Henrietta Lacks' cell line emerged today in a
wide range of publications, including a Nature journal piece that
said it was not a precedent.
The article was co-authored by Francis
Collins
, head of the NIH, and Kathy Hudson, deputy director for
science, outreach and policy at the NIH.

“It is important to note, however,
that we are responding to an extraordinary situation here, not
setting a precedent for research with previously stored,
de-identified specimens. The approach we have developed through
working with the Lacks family is unique because HeLa cells were taken
and used without consent, and gave rise to the most widely used human
cell line in the world, and because the family members are known by
name to millions of people.”

The restrictions on use of the cell
lines came about after a flap erupted about their recent use without
the knowledge of her descendants. (The California Stem Cell Report carried a commentary on it yesterday.) Rebecca Skloots, author of the
best-seller, “The Immortal Life of Henrietta Lacks,” wrote about
the controversy in a March 23 op-ed piece in the New York Times. She
said,
In the article, Skloots said,

“Imagine if someone secretly sent
samples of your DNA to one of many companies that promise to tell you
what your genes say about you. That report would list the good news
(you’ll probably live to be 100) and the not-so-good news (you’ll
most likely develop Alzheimer’s, bipolar disorder and maybe
alcoholism). Now imagine they posted your genetic information online,
with your name on it. Some people may not mind. But I assure you,
many do: genetic information can be stigmatizing, and while it’s
illegal for employers or health insurance providers to discriminate
based on that information, this is not true for life insurance,
disability coverage or long-term care.

“'That is private family
information,” said Jeri Lacks-Whye, Lacks’s granddaughter. “It
shouldn’t have been published without our consent.'”

Nature also carried a Q&A with Collins in which he said,

“This has wrapped in it science,
scientific history, ethical concerns, the bringing together of people
of very different cultures, a family with all the complications that
families have.”

In the Wall Street Journal this
morning, Ron Winslow described the arrangement with the NIH like
this.

“Under the pact, two descendants of
Ms. Lacks will serve on a six-member panel with scientists to review
proposals from researchers seeking to sequence the DNA of cell lines
derived from her tumor or to use DNA profiles of such cells in their
research. That gives family members a highly unusual voice in who
gets access to personal health information.

Terms call for controlled access to the
genomic data and credit to the Lacks family in papers and scientific
presentations based on the research done with the DNA data.”

In an interview in The Scientist,
Skloots, who was involved in the Lacks-NIH negotiations, said the
Lacks family asked for her participation.

“The only reason I was involved in
this is because scientists did this without the family’s consent
and then it got all of this press coverage, and no one asked the
question, 'Did the family give consent?' So I sort of waded back
in.”

She continued, 

“That OpEd that I
wrote was the first time I’d ever publicly expressed an opinion,
which was, 'Really?!? Are we going to continue to not ask the Lacks
family questions?' I was kind of shocked in a sense that nobody
thought to raise that issue.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/7XRzMDgIWjo/skloots-collins-and-more-on-henrietta.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Skloots, Collins and More on Henrietta Lacks' Cell Line Deal

The Henrietta Lacks Story and Eggs, Money and Motherhood

Posted: August 7, 2013 at 8:56 pm

The legacy of Henrietta Lacks popped up
again today in a piece in the New York Times that should
resonate among stem cell researchers and within the stem cell
industry.
It even has a current hook involving
California legislation to permit women to sell their eggs for the
purposes of scientific research – a bill that is now on the desk of
Gov. Jerry Brown.
The issues in the Lacks saga involve ownership of human
cells, trafficking in them and informed consent, all of which surface in one form or another in the state legislation.
But first a refresher on Henrietta
Lacks. She was an African-American woman who died in 1951 of cervical
cancer at the age of 31. Shortly before her death, physicians removed
some of her tumor cells, and, as recounted in today's NYTimes article
by Carl Zimmer,

“They later discovered that the cells
could thrive in a lab, a feat no human cells had achieved before.

"Soon the cells — nicknamed HeLa cells
— were being shipped from Baltimore around the world. In the 62
years since — twice as long as Ms. Lacks’s own brief life — her
cells have been the subject of more than 74,000 studies, many of
which have yielded profound insights into cell biology, vaccines, in
vitro fertilization and cancer.”

But Lacks never consented to her cells'
being studied, a situation not uncommon at the time, nor did her
family know about the situation until 1973. The complete story was
chronicled in 2010 in a best-selling book, “The Immortal Life of
Henrietta Lacks
," by Rebecca Skloot.
Zimmer noted in today's article,

“For 62 years, (Lacks') family has
been left out of the decision-making about that research. Now, over
the past four months, the National
Institutes of Health has come to an agreement with the Lacks
family to grant them control over how Henrietta Lacks’s genome is
used.”

The particulars involving her genome
are in Zimmer's story. But the article implicitly raises anew
questions that make many scientists uncomfortable. Often they contend
that the situation involving Lacks could not occur today because of
higher ethical standards. Standards ARE higher today. But problems
continue to arise in the scientific community, including the sale a few years ago of willed body parts at UCLA for $1.5 million to private medical companies.
Development of products based on human
stem cells promises even greater rewards, with billion-dollar
blockbuster therapies not out of the range of possibilities. Profit
and the desire to record a stunning research triumph are powerful
motivators. They can lead to short cuts and dubious practices, such
as seen in the Korean stem cell scandals of 2006.
So we come to whether women who donate
their eggs for stem cell research can give truly informed consent
when they surrender all rights to whatever products may result from
parts of their bodies, as is common on such consent agreements. Or
for that matter, what about the men who give up adult cells for
reprogramming to a pluripotent state? Can they really understand the
likelihood of a billion dollar product being generated with the help
of their contribution? On the other hand, can the donors also truly
understand that they are probably more likely to be struck by
lightning than have their body parts result in a medical blockbuster?
These considerations may seem
insignificant to some in science. But to grasp their full
implications, one only has to read a few of the nearly 200 reader
comments today on Zimmer's article today. Here is a sample.
From Frank Spencer-Molloy in
Connecticut:

“(T)the Lacks family was robbed.
Scores of companies profited to the tune of tens of millions of
dollars from products they made derived from Henrietta Lacks'
cancerous cells. Maybe this will provide some impetus to a wider
consideration of the rights patients are entitled to when their
tissues are cloned and disseminated to other researchers and
ultimately put to use in profit-making ventures.”

From Robbie in New York City:

“At the very least, this family needs
to be financially compensated for the anguish of their discovery and
for the time and energy they've put into pursuing their rights. In my
opinion, they also deserve a portion of any commercial gain that's
been made using the HeLa cells. It is only through having to give
away money that the powerful learn manners.”

From Julia Himmel in New York City:

“It is absolutely true that
scientists have had a blind spot when it came to the human element of
the HeLa cells.”

The pay-for-eggs legislation (AB926)
now before Gov. Brown requires informed consent from those who
provide eggs. Opponents of the measure, however, argue that truly
informed consent from some women could be actually impossible because
of economic pressures felt by the women. Writing in The Sacramento Bee last month, Diane Tober and Nancy Scheper-Hughes said,

“Allowing a market in eggs for
research would reach beyond the current pool to target women who may
be motivated by dire need. How many low-income women might consider
selling their eggs, multiple times, to feed their children or pay the
rent?”

Even the fertility industry group
sponsoring the legislation acknowledges that informed consent can be
problematic. A 2012 news release from the American Society for
Reproductive Medicine
said, 

“Prospective egg donors must
assimilate a great deal of information in the informed consent
process, yet it remains difficult to determine the extent of their
actual understanding of egg donation and its potential risks.”

The story of the treatment of Henrietta
Lacks and her descendants is a poor commentary on science and
medicine. Yet it resonates with the public, which is keenly sensitive
to scientific and medical abuses, even in situations that did not
appear to be abuses at the time.

Stem cell research already is burdened by its own
particular moral and religious baggage. With
commercialization of new, pluripotent stem cell therapies coming ever
closer, the last thing the field needs is contemporary version of the
Lacks affair. It would behoove researchers and the stem cell industry
to walk with more than normal care as they manipulate products that
are tied inextricably to visions of both motherhood and money.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/oncdCzO4V18/the-henrietta-lacks-story-and-eggs.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on The Henrietta Lacks Story and Eggs, Money and Motherhood

Whoifwhat: Stem Cell Therapy- Knees, Hip, Back, etc.! – Video

Posted: August 7, 2013 at 4:47 pm


Whoifwhat: Stem Cell Therapy- Knees, Hip, Back, etc.!
It works: Now in St. Louis, New York Phily: coming to your town soon ! Using stem cells from belly fat ( got any) platelets to mark area an injection is ...

By: whoifwhat

Original post:
Whoifwhat: Stem Cell Therapy- Knees, Hip, Back, etc.! - Video

Posted in Stem Cell Videos | Comments Off on Whoifwhat: Stem Cell Therapy- Knees, Hip, Back, etc.! – Video

Gum Tissue Stem Cells Heal Fast And Fight Inflammation

Posted: August 7, 2013 at 3:49 pm

August 6, 2013

April Flowers for redOrbit.com Your Universe Online

A new study from the Ostrow School of Dentistry of the University of Southern California (USC) reveals stem cells found in mouth tissue can relieve inflammatory disease, as well as become other types of cells.

The study, published in a recent issue of the Journal of Dental Research, focused on gingival mesenchymal stem cells (GMSC) that are found in the gingival, or gum tissue, of the mouth. Like other stem cells, GMSC have the ability to develop into different types of cells as well as affect the immune system.

Gingiva is very unique in our body, says Professor Songtao Shi, associate professor at the Center for Craniofacial Molecular Biology. It has much less inflammatory reaction and heals much faster when compared to skin.

Before this study, the developmental origins and abilities of GMSC had not been fully demonstrated. The USC researchers reveal there are two types of GMSC. The first type, M-GMSC, arrives from the mesoderm layer of cells during embryonic development. The second type, N-GMSC, originate from cranial neural crest cells that develop into many important structures of the head and face. N-GMSC were found to comprise 90 percent of the gingival stem cells.

M-GMSC and N-GMSC vary dramatically in their abilities, the team found. In addition to being easier to change into other types of cells, including neural and cartilage-producing cells, N-GMSC also have more of a healing effect on inflammatory disease than M-GMSC. When mice with dextrate sulfate sodium-induced colitis an inflamed condition of the colon received transplants of N-GMSC, the inflammation was dramatically reduced.

The study findings suggest the stem cells in the gingiva obtained via a simple biopsy of the gums may have important medical applications in the future.

We will further work on dissecting the details of the gingiva stem cells, especially their notable immunoregulatory property, says Xingtian Xu, specialized lab technician at the Ostrow School of Dentistry Center for Craniofacial Molecular Biology.

Through the study of this unique oral tissue, we want to shed the light on the translational applications for improving skin wound healing and reducing scar formation.

See original here:
Gum Tissue Stem Cells Heal Fast And Fight Inflammation

Posted in Stem Cells | Comments Off on Gum Tissue Stem Cells Heal Fast And Fight Inflammation

Page 2,293«..1020..2,2922,2932,2942,295..2,3002,310..»